NEW YORK, Nov. 22, 2017 /PRNewswire/ -- If you want a Stock Review on PSDV, TTPH, CTLT, or LCI then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. On Tuesday, the NASDAQ Composite ended the day at 6,862.48, up 1.06%; the Dow Jones Industrial Average edged 0.69% higher, to finish at 23,590.83; and the S&P 500 closed at 2,599.03, marginally gaining 0.65%. Gains were broad based as all sectors finished the trading session in green. DailyStockTracker.com has initiated research reports on the following Drugs - Generic stocks: pSivida Corp. (NASDAQ: PSDV), Tetraphase Pharmaceuticals Inc. (NASDAQ: TTPH), Catalent Inc. (NYSE: CTLT), and Lannett Co. Inc. (NYSE: LCI). Daily Stock Tracker published comprehensive and free research reports on these stocks today at: http://dailystocktracker.com/register/
pSivida
Watertown, Massachusetts-based pSivida Corp.'s stock finished Tuesday's session 3.15% higher at $1.31 with a total trading volume of 570,811 shares. The stock has gained 11.97% over the past three months. The Company's shares are trading above their 50-day moving average by 6.87%. Moreover, shares of pSivida, which develops sustained-release drug-delivery products for the treatment of chronic eye diseases in the US and the UK, have a Relative Strength Index (RSI) of 57.93.
On November 08th, 2017, research firm Laidlaw initiated a 'Buy' rating on the Company's stock, with a target price of $5 per share. PSDV complete research report is just a click away and free at: http://dailystocktracker.com/registration/?symbol=PSDV
Tetraphase Pharmaceuticals
Shares in Watertown, Massachusetts headquartered Tetraphase Pharmaceuticals Inc. rose 1.74%, ending yesterday's session at $6.44 with a total trading volume of 422,534 shares. The stock has 62.22% over the past twelve months and 59.80% on an YTD basis. The Company's shares are trading below their 50-day moving average by 2.88%. Moreover, shares of Tetraphase Pharma, which develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections, have an RSI of 51.55.
On November 06th, 2017, research firm H.C. Wainwright reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $15 a share to $17 a share. The complimentary report on TTPH can be downloaded at: http://dailystocktracker.com/registration/?symbol=TTPH
Catalent
On Tuesday, Somerset, New Jersey headquartered Catalent Inc.'s stock saw a rise of 1.06%, to close the day at $38.91. A total volume of 798,970 shares was traded. The Company's shares have advanced 11.46% in the previous three months, 55.52% over the last twelve months, and 44.32% on an YTD basis. The stock is trading above its 200-day moving average by 11.59%. Additionally, shares of Catalent, which provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide, have an RSI of 43.67. Sign up for your complimentary research report on CTLT at: http://dailystocktracker.com/registration/?symbol=CTLT
Lannett
Shares in Philadelphia, Pennsylvania-based Lannett Co. Inc. ended the day 3.59% higher at $24.55. A total volume of 973,527 shares was traded, which was above their three months average volume of 806.60 thousand shares. The stock has gained 52.48% in the previous three months, 13.92% over the last twelve months, and 11.34% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 15.78% and 17.62%, respectively. Furthermore, shares of Lannett, which develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the US, have an RSI of 61.19. Get free access to your research report on LCI at: http://dailystocktracker.com/registration/?symbol=LCI
--
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected] Phone number: (207)331-3313Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Advertisement
pSivida
Watertown, Massachusetts-based pSivida Corp.'s stock finished Tuesday's session 3.15% higher at $1.31 with a total trading volume of 570,811 shares. The stock has gained 11.97% over the past three months. The Company's shares are trading above their 50-day moving average by 6.87%. Moreover, shares of pSivida, which develops sustained-release drug-delivery products for the treatment of chronic eye diseases in the US and the UK, have a Relative Strength Index (RSI) of 57.93.
Advertisement
On November 08th, 2017, research firm Laidlaw initiated a 'Buy' rating on the Company's stock, with a target price of $5 per share. PSDV complete research report is just a click away and free at: http://dailystocktracker.com/registration/?symbol=PSDV
Tetraphase Pharmaceuticals
Shares in Watertown, Massachusetts headquartered Tetraphase Pharmaceuticals Inc. rose 1.74%, ending yesterday's session at $6.44 with a total trading volume of 422,534 shares. The stock has 62.22% over the past twelve months and 59.80% on an YTD basis. The Company's shares are trading below their 50-day moving average by 2.88%. Moreover, shares of Tetraphase Pharma, which develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections, have an RSI of 51.55.
On November 06th, 2017, research firm H.C. Wainwright reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $15 a share to $17 a share. The complimentary report on TTPH can be downloaded at: http://dailystocktracker.com/registration/?symbol=TTPH
Catalent
On Tuesday, Somerset, New Jersey headquartered Catalent Inc.'s stock saw a rise of 1.06%, to close the day at $38.91. A total volume of 798,970 shares was traded. The Company's shares have advanced 11.46% in the previous three months, 55.52% over the last twelve months, and 44.32% on an YTD basis. The stock is trading above its 200-day moving average by 11.59%. Additionally, shares of Catalent, which provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide, have an RSI of 43.67. Sign up for your complimentary research report on CTLT at: http://dailystocktracker.com/registration/?symbol=CTLT
Lannett
Shares in Philadelphia, Pennsylvania-based Lannett Co. Inc. ended the day 3.59% higher at $24.55. A total volume of 973,527 shares was traded, which was above their three months average volume of 806.60 thousand shares. The stock has gained 52.48% in the previous three months, 13.92% over the last twelve months, and 11.34% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 15.78% and 17.62%, respectively. Furthermore, shares of Lannett, which develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the US, have an RSI of 61.19. Get free access to your research report on LCI at: http://dailystocktracker.com/registration/?symbol=LCI
--
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected] Phone number: (207)331-3313Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/stock-performance-review-on-generic-drugs-industry----psivida-tetraphase-pharma-catalent-and-lannett-300560898.html
SOURCE dailystocktracker.com
